|
Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations. |
• BAQSIMI° (nasal glucagon) – Lilly
In severe hypoglycaemia in diabetic patients aged 4 years and over (Prescrire Int n° 232).
Nasal glucagon: easier to use than subcutaneous or intramuscular forms.
Glucagon, a hormone that raises blood glucose levels, is an essential drug for treating hypoglycaemia in patients with insulin-treated diabetes who have lost consciousness.
Glucagon has been available for many years as a powder for reconstitution as a solution for subcutaneous or intramuscular injection.
Glucagon is now marketed in Europe as a powder for administration as a dry nasal spray (Baqsimi°). Intranasally administered and injected glucagon have similar efficacy. The ease of use of the ready-to-use spray device is a therapeutic advance in a situation where urgent treatment is required, especially in non-medical settings, earning nasal glucagon a place on this year's Honours List. It is important that the carers, family and friends of patients with diabetes know when and how to use this product.
A Pilule d'Or (Golden Pill) is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available. Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations. Drugs deemed "Noteworthy" provide a modest improvement in patient care.
SEE: > About the Prescrire Drug Awards for 2021
|
> The Prescrire Drug Awards for 2021
Download the full article:
FREE "The Prescrire Awards for 2021" Prescrire International 2022; 31 (235): 79-82. (pdf, free)
Back to "The Prescrire Awards for 2021">
©Prescrire February 2022
|
Share |
|
|
Enjoy full access to Prescrire International, and support independent information
|